Status:
RECRUITING
Systemic Neoadjuvant and Adjuvant Control by Precision Medicine in Rectal Cancer
Lead Sponsor:
Helsinki University Central Hospital
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
Rectal cancer represents the most complex area of multidisciplinary treatment in bowel surgery. In 2017, there were 1221 new rectal cancers in Finland. The prognosis of colorectal cancer (CRC) patient...
Eligibility Criteria
Inclusion
- rectal adenocarcinoma,
- World Health Organization (WHO) performance status 0-1, assessed by the MDT to be able to undergo capecitabine and oxaliplatin (CAPOX) treatment, 3) extramural vein invasion by magnetic resonance imaging (mrEMVI+) and
- 4\) assessed by the multi-disciplinary team (MDT) to require either radiotherapy (RT) or long chemoradiotherapy (CRT) by the current standards.
Exclusion
- deficient mismatch repair (MMR) status,
- non-dihydropyrimidine dehydrogenase (DPYD) genotype,
- a contraindication to capecitabine, oxaliplatin or RT, or
- failing in blood tests that describe the adequate circulatory, liver and kidney function for chemotherapy.
Key Trial Info
Start Date :
December 20 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2031
Estimated Enrollment :
93 Patients enrolled
Trial Details
Trial ID
NCT04842006
Start Date
December 20 2021
End Date
December 31 2031
Last Update
March 6 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Helsinki University Central Hospital
Helsinki, Uusimaa, Finland, 00029
2
Tampere University Hospital
Tampere, Finland, 33520